Review
Open access
Spatial determinants of pathological complete response and residual disease after neoadjuvant therapy in breast cancer
Medicine
Abstract
Highlights • Spatial immune architecture adds information beyond immune-cell abundance.• CD8-tumor proximity and TLS quality are linked to neoadjuvant response.• Stromal, vascular, and metabolic barriers may preserve resistant regions.• Treatment reshapes spatial ecosystems before response endpoints emerge.• Residual disease is a treatment-selected ecosystem with prognostic value.